0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Incyte closes 5% higher bolstered by Zynyz data, Guggenheim note [Seeking Alpha]

Incyte Corporation (INCY)  More Company Research Source: Seeking Alpha
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
The gain represented the biotech's largest daily one since July 9, when it closed up ~4.4%. The ESMO data showed that the median PFS in the Zynyz + chemo group was 9.3 months compared to 7.4 months in the chemo only arm. In a note, Guggenheim's Michael Schmidt said the Zynyz regimen would lead to a "robust uptake in a high unmet need population." He rates Incyte a buy with a $92 price target (~39% upside based on Sept. 16 close), just raised from $86. Recommended For You More Trending News Recommended For You More Trending News About INCY Stock Related Stocks Trending Analysis Trending News [Read more]
IMPACT SNAPSHOT EVENT TIME: INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
INCY alerts
from News Quantified
INCY
NEWS
INCY
Earnings
INCY
Analyst Actions
INCY
SEC Filings
Stockreport

Incyte closes 5% higher bolstered by Zynyz data, Guggenheim note [Seeking Alpha]

Incyte Corporation  (INCY) 
More Company Research Source: Seeking Alpha
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
The gain represented the biotech's largest daily one since July 9, when it closed up ~4.4%. The ESMO data showed that the median PFS in the Zynyz + chemo group was 9.3 months compared to 7.4 months in the chemo only arm. In a note, Guggenheim's Michael Schmidt said the Zynyz regimen would lead to a "robust uptake in a high unmet need population." He rates Incyte a buy with a $92 price target (~39% upside based on Sept. 16 close), just raised from $86. Recommended For You More Trending News Recommended For You More Trending News About INCY Stock Related Stocks Trending Analysis Trending News [Read more]
IMPACT SNAPSHOT
EVENT TIME:
INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS